Summary measures were a useful alternative for analyzing therapeutic clinical trial data

Journal of Clinical Epidemiology

Volumn 59, Issue 4, 2006, Pages 387-392

  Carusone, Soo Chan ^a   Goldsmith, Charlie H ^a   Smieja, Marek ^a   Loeb, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Analysis; Area under the curve; Clinical trials; Pooled index; Summary measures

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE; RIFAMPICIN;

ADULT; AGED; ALZHEIMER DISEASE; ANAMNESIS; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DATA INTERPRETATION, STATISTICAL; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RIFAMPIN; TREATMENT OUTCOME;

EID: 33645030878     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2005.05.009     Document Type: Article

References (22)

1. International Conference on Harmonization E9 Expert Working Group ICH harmonised tripartite guideline: statistical principles for clinical trials Stat Med 18 1999 1905 1942
2. R.S. Roberts Pooled outcome measures in arthritis: the pros and cons J Rheumatol 20 1993 566 567
3. C.H. Goldsmith, H.A. Smythe, and A. Helewa Interpretation and power of a pooled index J Rheumatol 20 1993 575 578
4. J.N. Matthews, D.G. Altman, M.J. Campbell, and P. Royston Analysis of serial measurements in medical research BMJ 300 1990 230 235
5. M. Schiff A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies Clin Ther 25 2003 993 1001
6. B. Pham, A. Cranney, M. Boers, A.C. Verhoeven, G. Wells, and P. Tugwell Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials J Rheumatol 26 1999 712 716
7. K. Sadik, and G. Wilcock The increasing burden of Alzheimer disease Alzheimer Dis Assoc Disord 17 Suppl 3 2003 S75 S79
8. K. Rockwood, M. Wallack, and R. Tallis The treatment of Alzheimer's disease: success short of cure Lancet Neurol 2 2003 630 633
9. H.A. Smythe, A. Helewa, and C.H. Goldsmith "Independent assessor" and "pooled index" as techniques for measuring treatment effects in rheumatoid arthritis J Rheumatol 4 1977 144 152
10. M.B. Loeb, D.W. Molloy, M. Smieja, T. Standish, C.H. Goldsmith, J. Mahony, S. Smith, M. Borrie, E. Decoteau, W. Davidson, A. McDougall, J. Gnarpe, M. O'Donnell, and M. Chernesky A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease J Am Geriatr Soc 52 2004 381 387
11. B.J. Balin, H.C. Gerard, E.J. Arking, D.M. Appelt, P.J. Branigan, J.T. Abrams, J.A. Whittum-Hudson, and A.P. Hudson Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain Med Microbiol Immunol (Berl) 187 1998 23 42
12. T.I. Standish, D.W. Molloy, M. Bedard, E.C. Layne, E.A. Murray, and D. Strang Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS) J Am Geriatr Soc 44 1996 712 716
13. D.W. Molloy, W.E. McIlroy, G.H. Guyatt, and J.A. Lever Validity and reliability of the Dysfunctional Behaviour Rating Instrument Acta Psychiatr Scand 84 1991 103 106
14. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-83;17:37-49.
15. M.P. Lawton, and E.M. Brody Assessment of older people: self-maintaining and instrumental activities of daily living Gerontologist 9 1969 179 186
16. D.W. Molloy, E. Alemayehu, and R. Roberts Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination Am J Psychiatry 148 1991 102 105
17. R.B. Mani The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint Stat Med 23 2004 305 314
18. D.M. van der Heijde, M. van't Hof, P.L. van Riel, and L.B. van de Putte Development of a disease activity score based on judgment in clinical practice by rheumatologists J Rheumatol 20 1993 579 581
19. C. Bombardier, J. Ware, I.J. Russell, M. Larson, A. Chalmers, and J.L. Read Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trial Am J Med 81 1986 565 578
20. M.A. Raskind, E.R. Peskind, L. Truyen, P. Kershaw, and C.V. Damaraju The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial Arch Neurol 61 2004 252 256
21. S.A. Reines, G.A. Block, J.C. Morris, G. Liu, M.L. Nessly, C.R. Lines, B.A. Norman, C.C. Baranak, and Rofecoxib Protocol 091 Study Group Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 62 2004 66 71
22. L.J. Thal, M. Grundman, J. Berg, K. Ernstrom, R. Margolin, E. Pfeiffer, M.F. Weiner, E. Zamrini, and R.G. Thomas Idebenone treatment fails to slow cognitive decline in Alzheimer's disease Neurology 61 2003 1498 1502